

1 **Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue**

2
3 Richard D. Bell^{1,2,*}, Matthew Brendel^{2,*}, Maxwell Konnaris¹, Justin Xiang³, Miguel Otero^{1,2}, Mark
4 A. Fontana^{1,2}, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus
5 Erythematosus (AMP RA/SLE) Consortium, Edward DiCarlo¹, Jennifer Anolik⁴, Laura Donlin¹,
6 Dana Orange^{1,5}, H. Mark Kenney⁴, Edward M. Schwarz^{4†}, Lionel B Ivashkiv^{1,2†} and Fei Wang^{2†}

7
8 *, † Authors contributed equally

9
10 Affiliations: ¹Hospital for Special Surgery, ²Weill Cornell Medical College, ³Horace Greely High
11 School, ⁴University of Rochester Medical Center, and ⁵The Rockefeller University

12
13 Corresponding Author:

14 Richard D. Bell, PhD

15 515 E 71st New York, NY

16 bellr@hss.edu

18 **Abstract**

19
20 Rheumatoid arthritis (RA) is a complex immune-mediated inflammatory disorder in which
21 patients suffer from inflammatory-erosive arthritis. Recent advances on histopathology
22 heterogeneity of RA pannus tissue revealed three distinct phenotypes based on cellular
23 composition (pauci-immune, diffuse and lymphoid), suggesting distinct etiologies that warrant
24 specific targeted therapy. Thus, cost-effective alternatives to clinical pathology phenotyping are
25 needed for research and disparate healthcare. To this end, we developed an automated multi-
26 scale computational pathotyping (AMSCP) pipeline with two distinct components that can be

27 leveraged together or independently: 1) segmentation of different tissue types to characterize
28 tissue-level changes, and 2) cell type classification within each tissue compartment that
29 assesses change across disease states. Initial training and validation were completed on 264
30 knee histology sections from mice with TNF-transgenic (n=233) and injected zymosan induced
31 (n=32) inflammatory arthritis. Peak tissue segmentation performance with a frequency weighted
32 mean intersection over union was 0.94 ± 0.01 and peak cell classification F1 was 0.83 ± 0.12 .
33 We then leveraged these models and adapted them to analyze RA pannus tissue clinically
34 phenotyped as pauci-immune (n=5), diffuse (n=28) and lymphoid (n=27), achieving peak cell
35 classification performance with F1 score of 0.81 ± 0.06 . Regression analysis demonstrated a
36 highly significant correlation between AMSCP of lymphocyte counts and average Krenn
37 Inflammation Score ($\rho = 0.88$; $p < 0.0001$). While a simple threshold of 1.1% of plasma cells
38 demonstrated the phenotyping potential of our automated approach vs. a clinical pathologist
39 with a sensitivity and specificity of 0.81 and 0.73. Taken together, we find AMSCP to be a
40 valuable cost-effective method for research. Follow-up studies to assess its clinical utility are
41 warranted.

42

43 **Introduction**

44 Disease pathotyping with histopathology, the discovery of disease subtypes using target
45 organ histology, is a critical step in understanding etiology and response to therapy in
46 heterogeneous diseases, like rheumatoid arthritis (RA). Our understanding of RA, which is a
47 chronic, inflammatory joint disease, has greatly benefited from histopathology subtyping
48 because the disease has distinct and disparate etiologies with largely stable pathotypes [1, 2]
49 that show differential response to therapy [3-7]. However, the process of pathotyping a patient
50 can be resource intensive involving both basic and immune-stains requiring a high level of
51 expertise by pathologists to interpret tissue and cellular histologic features, and prone to inter-

52 and intra-observer variations [8, 9]. More cost effective and efficient procedures need to be
53 developed in order incorporate these types of data into a precision medicine decision making
54 process.

55 Recent work describing RA pathotypes uncover three distinct synovial pathotypes 1)
56 cellular dense, lymphocyte rich (lymphoid), 2) myeloid rich with few lymphocytes
57 (diffuse/myeloid), and 3) fibroblast rich (pauci-immune); which are identifiable through distinct
58 cellular and tissue level changes within synovial joint biopsies [10-14]. These pathotypes also
59 correlate with antibody positivity (i.e. anti-citrullinated peptide antibodies) with the lymphoid type
60 enriched in antibody positive patients whereas both the diffuse/myeloid and pauci-immune types
61 have equal contributions of both antibody positive and negative patients. This aligns with
62 preclinical models that rely on antibody dependent (e.g. Collagen Induced Arthritis and Serum
63 Induced Arthritis) and independent mechanism (e.g. humanized TNF Transgenic and Zymosan
64 Induced Arthritis) to study disease and are phenotypically similar to these pathotypes [15].
65 Thus, tools that allow us to study both murine and human pathology would improve our overall
66 understanding of this heterogeneous disease.

67 Computational tools to study histological changes have been shown to augment
68 pathologist workflows and allow for the identification of disease specific patterns [16]. In
69 particular, machine learning, and specifically deep learning, is a data-driven framework that has
70 recently had success in the automated analysis of musculoskeletal imaging data [17].
71 Additionally, computational tools can automate and provide a more holistic analysis a wide
72 variety of histopathologic tissue and cell-level changes to enable a more detailed understanding
73 of disease subtypes. However, automated and comprehensive tool to study both tissue and cell
74 type specific changes in arthritis that can quantify therapeutic or clinically meaningful differences
75 has not yet been developed [17].

76 In this work, we developed an automated multi-scale computational pathotyping
77 (AMSCP) model to analyze tissue and cell-level changes during the progression of inflammatory

78 arthritis. This model can pathotype both mouse and human inflammatory arthritis in therapeutic
79 intervention studies and clinical meaningful scenarios. We leveraged innovative transfer- and
80 active- learning techniques to improve model performance and workload efficiency. Our
81 modeling framework consists of two distinct components that can be utilized together or
82 independently, (1) a method to segment different tissue types to characterize tissue-level
83 changes and (2) a method to classify cell types within each tissue compartment to study how
84 these change across disease states. We utilized two mouse models of inflammatory arthritis to
85 train and validate our computational models with subsequent implementation on additional
86 datasets to measure therapeutic efficacy, known biologic differences and discover novel
87 pathologic changes. Then, we utilize a human synovial biopsy data set from the Accelerating
88 Medicines Partnership Rheumatoid Arthritis (AMP-RA) to demonstrate our model's utility in a
89 clinical setting by classifying lymphoid pathotypes from diffuse/myeloid pathotype and identifying
90 cell types associated with the pauci-immune pathotype while preserving spatial cell-level data.

91

92 **Methods**

93 *Dataset Description*

94 All mouse work was approved by the University Committee on Animal Resources at the
95 University of Rochester Medical Center and the Institutional Animal Care and Use Committee at
96 the Hospital for Special Surgery. Whole slide images (WSIs) of sagittal mouse knee sections
97 were taken from two different mouse models of inflammatory arthritis and the accompanying
98 controls for segmentation experiments (**Supplemental Figure 1A**). Batch A consisted of male
99 and female TNF Transgenic mice (TNF-Tg, n=47) and wild-type littermates (WT, n = 15) used in
100 a previous publication [18, 19]. Batch B consisted of male and female knees that received intra-
101 articular injections of 180ug of Zymosan to induce Zymosan Induced Arthritis (ZIA, n = 24) and
102 control contralateral limbs (Control, n = 8) [20] that were euthanized on Day 7 after injection.
103 Different batches were used to test model generalizability across different biological

104 mechanisms of arthritis development, differences in H&E staining protocols and slide scanner
105 used to digitally capture slides at 40x magnification (Batch A: VS120 Olympus, 0.173 μm per
106 pixel; Batch B: CS2 Aperio Leica, 0.253 μm per pixel).

107 To further test model generalizability, 2 different holdout datasets were used to validate
108 the model: 1) H&E-stained sagittal knee WSIs from Bell et al [18, 19] and 2) Orange G-H&E
109 stained sagittal knee WSIs from Kenney et al [21]. Slides from Bell et al were ensured to not be
110 used in the initial model training, internal validation or testing. These included slides from 6-
111 month-old male TNF-Tg (n=33 slides from 14 knees) and WT littermates (n=43 slides from 17
112 knees), and slides from 9.5 month old male TNF-Tg mice (Anti-TNF: n=24 slides from 8 knees;
113 Placebo: n= 29 slides from 10 knees) and WT littermates (Placebo: n=42 slides from 15 knees)
114 either treated with a 6 week course of Anti-TNF antibodies or Placebo control. To generate
115 downstream measurements of tissues of interest, a region of interest (ROI) was drawn from the
116 tibial growth plate to femoral growth plate including the anterior and posterior extra articular
117 tissue.

118 WSIs of H&E-stained human synovial biopsies were collected from the Accelerating
119 Medicines Partnership Rheumatoid Arthritis (AMP-RA) Phase II consortium [22]. In short,
120 synovial tissue biopsies were acquired from RA patients at 13 different clinical sites in the
121 United States and 2 from the United Kingdom from October 2016 to February 2020. The study
122 was performed in accordance with protocols approved by the institutional review board at each
123 site. The tissue was paraffin embedded, stained with H&E and imaged on a VS120 Olympus.
124 Board certified pathologists in the AMP-RA consortium classified each case as either lymphoid
125 (n = 27), diffuse/myeloid (n=28) or pauci-immune (n=5), and provided the Krenn inflammation
126 score for each case [23].

127

128 *Semantic Segmentation Annotation and Preprocessing*

129 Manual annotations were performed within QuPath [24] to assign labels for WSIs. To
130 test model performance across tissue types at different granularity, multiple different class
131 structures were tested (**Supplemental Figure 2**). Eleven different classes were manually
132 annotated, including synovium, muscle and tendon, growth plate, bone marrow, cortical bone,
133 trabecular bone, articular cartilage, meniscus, fat, bone marrow fat, and histology artifact (i.e.,
134 out of focus). A seven-class, nine-class, and ten-class segmentation task was generated by
135 merging histologically similar tissues, such as merging cartilage and meniscus into the same
136 class (**Supplemental Figure 2**). Overall, we estimate about 250 hours were spent annotating
137 the 11 tissue classes on 94 WSIs.

138 Due to the gigapixel nature of WSIs, the entire slide cannot be fed directly into a deep
139 learning model. Previous work has shown that WSIs can be broken into patches, in this case
140 512 pixel x 512 pixel, to perform downstream learning tasks [25]. For semantic segmentation, a
141 custom QuPath script was used to export patches at a 4x downsample while filtering out regions
142 of the scanned slide that lacked annotations or without tissue. Additionally, images were
143 normalized to mean 0 and standard deviation 1 by sampling a subset of patches to get mean
144 and standard deviation RGB statistics.

145

146 *Semantic Segmentation Models and Training Strategy*

147 Two different training strategies were employed to test model performances
148 (**Supplemental Figure 1B**). First, a mixed training strategy was used, in which slides from
149 Batch A and Batch B were mixed and randomly assigned to a training, validation, and test split,
150 using 70%, 15%, and 15% for each split, respectively (3 splits total). In this training strategy,
151 stratification was performed by batch and disease type to ensure even splitting into each set,
152 and each patch was split on the slide level to prevent data leakage across splits. Next a single
153 batch training strategy was tested to assess how site-specific differences in histology slides may

154 impact model performance [26]. In this training strategy, Batch A was used for the training and
155 validation sets, and Batch B was used as the held-out test set.

156 Data augmentation strategies were also tested to assess their impact across the
157 different training strategies (**Supplemental Figure 3**). We had three different levels of
158 augmentation tested, (1) None, (2) Low, (3) Medium, and (4) High. The python package
159 `imgaug`[27] as used to implement augmentation. Augmentation was applied in the following
160 way: (1) None had zero augmentation, (2) Low had 2-4 augmentation process applied 25% of
161 the time, (3) Medium had 3-7 augmentations applied 50% of the time and (4) High augmentation
162 had 5-11 augmentation process applied 50% of the time during training. Augmentation was
163 randomly selected from 11 different types of augmentations including, horizontal flip ($p = 0.5$),
164 coarse dropout or pixel dropout from 0.2x the original image resolution ($p=0.1$), one of three
165 different rotation types at 90° , 180° , and 270° , additive gaussian noise sampled from a normal
166 distribution with mean 0 and variance $0.2*255$, blur using gaussian kernel with sigma of 1.5,
167 hue modification using addition (-30,10) and saturation modification using multiplication (0.5,1.5)
168 and linear contrast (0.5,2), brightness adjustment both add(-30,30) and multiply (0.5,1.5), and
169 color change adjustment (3000,8000).

170 To compare segmentation performance using both conventional machine learning and
171 deep learning methods, we tested two different model architectures. A Random Forest (RF)
172 model implemented with OpenCV [28] in QuPath and an U-Net++ [29] deep learning model
173 implemented in PyTorch [30]. To train the RF, we first applied a Simple Linear Iterative
174 Clustering algorithm ($\sigma = 5$, spacing = 20 μm , Max Iterations = 1, Regularization = 0.01) in
175 which each over segmented area was considered a super-pixel. We then performed color and
176 shape feature extraction of each super-pixel, and calculated the average features of super-
177 pixels within 40 and 80 μms . These features were then used in the RF and the tissue class of
178 each super-pixel was used to supervise the model. After the RF was trained, its performance
179 was assessed fully in QuPath. For our deep learning pipeline, we utilized the

180 segmentation_models_pytorch [31] package for the UNET++ implementation with an ImageNet
181 pre-trained EfficientNet-B5 backbone for the encoder [32]. We utilized the combo loss, which
182 was the arithmetic average of the dice loss and binary cross entropy (BCE) loss during model
183 training [33]. A learning rate scheduler was used to train the model using a step size of 2 and a
184 gamma of 0.5. The learning rate started at 0.025 using the stochastic gradient descent (SGD)
185 optimizer with momentum (0.9) and regularization of 1×10^{-4} and was trained for 10 epochs.

186 When jointly training across 10 different classes, this model provided no prediction for
187 the meniscus class resulting in a mIOU of 0 ± 0 (Supplemental Figure 6), likely due to
188 insufficient training examples (Supplemental Figure 2; 0.9% frequency overall). As the meniscus
189 was important for downstream biological analyses, we developed a strategy to improve
190 predictions for this class. A second U-Net++ model was fine-tuned from the nine-class model
191 (i.e. the model that has cartilage and meniscus merged into one class) by changing the
192 prediction (final) layer specifically to predict between cartilage and meniscus. We then re-trained
193 the full model only on images and Ground Truth annotations (GTs) that contained either
194 cartilage or meniscus within the mixed training set.

195 Previous work had suggested that U-Net based semantic segmentation can have image
196 boundary level artifacts [34]. Therefore, we assessed how including patch level overlap for
197 prediction can improve model performance. We included experiments using no overlap, 50%
198 overlap and 66% overlap between them with images from both batches (**Supplemental Figure**
199 **4**). To analyze the results, we loop through all the predictions (N) for the entire WSI and
200 calculate a majority vote for each pixel after thresholding to removes low confidence predictions
201 (pixel value of 75). N can be variable depending upon the region, for example if it is on border,
202 but typically is between 4-9.

203

204 *Semantic Segmentation Model Evaluation, Inference on External Validation Set and Statistical*
205 *Evaluation*

206 To evaluate the semantic segmentation model performance for the validation and test
207 set slides with ground-truth labels, we calculated the mean Intersection over Union (mIOU) and
208 frequency-weighted mIOU to prevent very rare classes from drastically impacting overall model
209 performance [35]. All model hyperparameter optimization was performed on the validation set,
210 and once the above parameters were chosen the models were used to infer segmentation on
211 the test set and the mIOUs were calculated.

212 We used the optimal settings from the training/validation process to evaluate the model
213 performance on the held-out datasets. Pearson's correlation was used to compare the hand
214 drawn synovial tissue area reported in Bell et al [18] with model classified synovial tissue area.
215 The fine-tuned 10-class model was used to infer tissue segmentation on the held-out data [21,
216 36]. Specifically, the UNET++ 9 class model was used to predict tissues classes on each patch,
217 and if the nine-class model had a prediction output for the combined cartilage and meniscus
218 class on a patch, then the patch was passed through the fine-tuned 2 class model to assign to
219 either the meniscus or cartilage class. Predictions were merged by only allowing the fined tuned
220 predictions to be within the predictions from the combined Cartilage-Meniscus class. Once the
221 inference was complete, a ROI was drawn on each slide from femoral growth plate to tibial
222 growth plate around the joint to restrict the downstream analysis to the joint space, subchondral
223 bone, and synovial adjacent tissue. Tissue area was calculated and a One-Way ANOVA with
224 Tukey's post-hoc adjustment was used to detect significant differences.

225

226 *Cell Type Classification Framework and Preprocessing*

227 For cell type classification, a combination of transfer learning and active learning was
228 used to identify several different cell types that exist within the joint tissue. Cell type
229 classification can be broken into a two-step process, (1) segmentation and (2) classification. For
230 cell segmentation, transfer learning was used by leveraging a deep learning model, HoVer-Net
231 [37], pretrained on the PanNuke dataset [38], to extract nuclei regions. Image patches (1024 x

232 1024 pixels) at 40x magnification were given as inputs, and ROI contours of nuclei were
233 obtained to perform feature extraction upon. These nuclei with their features and labels (detailed
234 below) were then leveraged in a gradient boosted decision tree (GBDT) model to classify cells.

235 The input for the classifier was derived from features extracted from each ROI generated
236 by HoVer-Net. Specifically, every nuclei from the json file output of HoVer-Net was converted
237 into a ROI (.roi) file to be read into FIJI/ImageJ [39] for feature extraction using a custom script.
238 Detailed workflow for the ImageJ/FIJI analysis is described as follows. Each image was split
239 using the built-in color deconvolution [40] algorithm in FIJI into hematoxylin and eosin color
240 channels. For each channel the nuclei were measured for several different parameters,
241 including morphological quantities (area, perimeter, circularity, feret's diameter, feret angle,
242 aspect ratio, roundness, and solidity) and staining color quantities (mean, mode, min, max,
243 standard deviation, skewness, median, and kurtosis), and the nuclei ROI was enlarged to
244 calculate cell specific cytoplasmic H&E color information for each cell. Characteristics of
245 neighboring cells at several different distance ranges were used to include tissue level context
246 into cell type classification [41]. A final total of 854 features were extracted for the downstream
247 analysis.

248 Known healthy and pathologic cell types that contribute to inflammatory arthritis were
249 then annotated on both mouse and human tissues (**Supplemental Figures 8 and 10**). The
250 mouse proof-of-concept classification task consisted of bone-embedded cells, vessel cells,
251 adipo-stromal cells (both adipose and stromal cells within fatty tissue), synovial fibroblasts
252 (healthy and pathologic), chondrocytes, lymphocytes, and other synovial lining cells (healthy
253 and pathologic) as detailed in **Supplemental Figures 8**; annotated by subject-matter experts
254 familiar with histologic analysis of these cell types. These cells were annotated on six healthy,
255 eight mild disease and five severely diseased TNF-Tg knee sections. For human samples, a
256 clinically meaningful set of cell types were labeled by a senior pathologist, following a standard
257 cell type hierarchy (**Supplemental Figure 10**). These included stromal/connective tissue cells,

258 synovial lining cells, synovial fibroblasts, vascular endothelial cells, tissue
259 macrophages/histocytes, lymphocytes, and plasma cells. These cells were labeled on five
260 lymphoid, five diffuse and three pauci-immune cases. Nuclei were then mapped to manually
261 annotated nuclei by checking if a nuclei's centroid (as determined by Hover-Net) was within an
262 annotation mask.

263

264 *Cell Type Classification Model and Active Learning*

265 A total of 4,712 cells were annotated for mouse cell type classification from seven
266 different classes. Cells were labeled from a total of 19 different slides. A GBDT model was
267 trained for cell type classification, using 5-fold cross validation to select the best models. To
268 evaluate model performance, cell types were predicted for two different biological settings, (1) to
269 identify cell composition changes across different disease severities on the remaining cells
270 (>300,000) on the 19 slides, and (2) identify differences between male and female mice in the
271 context of disease progression in a held-out dataset [18]. Finally, average synovial inflammatory
272 infiltrate scores and average pannus invasion scores were correlated with lymphocyte and
273 synovial lining cell counts respectively (Spearman's Correlation).

274 Human annotation was the time-consuming step for the cell type classification pipeline.
275 Therefore, we applied the active learning strategy to improve the annotation efficiency for cell
276 annotation of human samples. To develop this strategy, we tested a proof-of-concept active
277 learning strategy using labeled data from the mouse H&E slides (**Supplemental Figure 9**).
278 Active learning is an iterative process that consists of three main steps, (1) annotation, (2)
279 model training, and (3) sample selection for further annotations. Its goal is to select the samples
280 that can lead to the largest model performance improvement when adding to the training data
281 after annotation. To validate the strategy, 100 different rounds of 5-fold cross-validation were
282 performed. Average F1-scores were reported for each class and a macro-F1 score was
283 additionally reported. 25 runs of 5-fold cross validation were removed due to cells from a single

284 class not being present in both the training and testing sets. For the training dataset for each
285 split, 5% of cells were first randomly selected as the first set of cells selected as being labeled
286 annotated. Subsequently, the GBDT classifier was trained using this randomly selected data.
287 Several different metrics for determining cells for annotation and subsequent model finetuning,
288 including smallest margin uncertainty [42], least confidence uncertainty [43] and entropy-based
289 uncertainty [42] were assessed. The top 5% of cells were added to the training dataset and the
290 cycle of model training and evaluation and new cell annotations continued until the entire
291 training dataset was used. A random selection of cells after shuffling was also tested to
292 compare model performance to the various active learning strategies. The package modal [44]
293 was leveraged in our implementation. Mean and 95% confidence intervals are reports for each
294 subset across the 75 different runs of 5-fold cross validation.

295

296 *Cell Classification Model Evaluations*

297 Confusion matrices were generated for model prediction along with F1-scores calculated as

298 $2 \cdot \frac{\text{precision} \cdot \text{recall}}{\text{precision} + \text{recall}}$, where $\text{precision} = \frac{TP}{TP+FP}$ and $\text{recall} = \frac{TP}{TP+FN}$, where TP, FP, FN stand for true

299 positives, false positives, false negatives. Models were tested using known cell types within
300 specific tissue types to evaluate the model qualitatively.

301

302 *Analysis of Human Synovial Biopsy Slides*

303 Active learning was then leveraged for human cell type classification using H&E-stained
304 slides of human synovial biopsy tissue of RA patients from the AMP consortium as described
305 above. Multiple rounds of cell type labeling were performed with the assistance of active
306 learning, to obtain a total of 2,639 cells grouped in seven different cell types, detailed in
307 Supplemental Figure 9 (stromal/connective tissue cells n=597, synovial lining cells n= 309,
308 synovial fibroblasts n = 189, vascular endothelial cells n = 486, Tissue Macrophages/Histocytes

309 n = 201, lymphocytes n = 826, and plasma cells n = 310). A cell type classification model using
310 GBDT with five-fold cross validation was trained on this dataset and inferences from the best
311 performing model applied to all cells on the slides within this patient cohort. Summary cell type
312 quantification (total cell counts and percent of total) was then assessed for each patient. Two
313 analyses were performed using the derived cell types from the cell classification model. First cell
314 type proportions were analyzed across different pathotypes. Specifically, statistical significance
315 testing using lymphocyte, plasma cell, and fibroblast slide proportions were evaluated across
316 pathotypes. Second, pathologist-derived, and clinically relevant Krenn inflammation scores were
317 correlated with Spearman's correlation to the counts of the lymphocytes for each slide to assess
318 disease severity across human samples.

319

320 *Visualization of Data*

321 Uniform Manifold Approximation and Projection [45] visualization was used for feature
322 representations between batches and cell type framework features. Masks for each class were
323 reimported into QuPath [24] for visualization purposes.

324

325 *Dataset and Code Availability*

326 All original data and analysis scripts will be provided upon reasonable request.

327

328 **Results**

329 *Deep Learning Segmentation Can Identify Major Tissue Types within Mouse Knee Histology* 330 *and Measure Therapeutic Response*

331 Several model training choices, including patch overlap, training strategy, and use of
332 different amounts of augmentation during training, were empirically derived from initial
333 experiments to inform the final training of the deep learning segmentation model (UNET++) [34,
334 46]. First, we tested if 0%, 50% or 66% patch overlap was more performative and determined

335 that 66% overlap performed the best (0% Overlap fwIOU: 0.72 ± 0.04 ; 50% Overlap fwIOU: 0.93
336 ± 0.02 ; 66% Overlap fwIOU: 0.95 ± 0.01 ; **Supplemental Figure 4A**). Qualitatively, there were
337 less tiling edge artifacts in the 66% overlap vs 50% overlap results (50% - Arrows
338 **Supplemental Figure 4B** vs **Figure 1**). Second, a mixed training strategy was shown to
339 overcome the large staining batch effect (**Supplemental Figure 5A**) commonly seen in
340 histology datasets with all levels of augmentation equally performative (**Supplemental Figure**
341 **5B**). However, if the data is restricted to a single batch and data augmentation is introduced,
342 model performance for the single batch training strategy becomes comparable to model
343 performance using the mixed strategy (High Augmentation UNET++: 0.81 ± 0.02 vs 0.80 ± 0.06
344 mIOU for mixed and single batch respectively), demonstrating the need for augmentation to
345 generalize across batches with this level of heterogeneity in staining and other imaging
346 variations (**Supplemental Figure 5B and C**). Thus, we choose to employ a mixed training
347 strategy, with 66% patch overlap and with high augmentation to optimize model performance
348 and generalizability.

349 Once the training strategy was established, model performance was benchmarked
350 across segmentation tasks at multiple tissue granularities and compared with a standard RF
351 model built-in to QuPath (**Figure 1**). As expected, as the number of different tissue types
352 increases, model performance decreases across both the RF model and UNET++ model, and
353 the DL model outperform the RF at all levels. Interestingly, the magnitude of change is smaller
354 for the UNET++ model compared to the RF model. When testing the UNET++ model, using the
355 ten-class granularity, model performance drops from 0.88 ± 0.06 mIOU for the cartilage and
356 meniscus class to 0.83 ± 0.05 mIOU for the cartilage class and 0.0 ± 0.0 mIOU for the meniscus
357 class indicating a complete loss of meniscus identification (**Supplemental Figure 6**). Because
358 defining the amount of cartilage and meniscus is an incredibly important pathologic readout in
359 joint diseases (e.g. pannus invasion at end stage arthritis), we developed a finely tuned two
360 class model and placed it sequentially after the 9-class model. Predictions from both were

361 incorporated during majority voting process and performance jumps for this fine-tuned resulting
362 ten-class model from 0.72 ± 0.01 mIOU to 0.82 ± 0.02 mIOU (**Figure 1A and B**). Specifically,
363 performance for the cartilage and meniscus classes were 0.9 ± 0.04 and 0.92 ± 0.05 ,
364 respectively. We additionally observe that the worst performing classes are the artifact class
365 and bone marrow fat class, the two most infrequent classes, suggesting that fine tuning may
366 work to improve performance for one or both (**Supplemental Figure 6**). Thus, for all
367 subsequent work we either used the 9-class model (termed Original model) for ease of
368 computation or the Fine-Tuned 10 class model for meniscus segmentation because these
369 provided the best predictive performance while encompassing the most amount of tissues.

370 After training the model on the mouse cohorts as described, the model was then
371 externally validated (i.e., completely independent of the training, testing and validation process
372 above) in two ways. 1) We first validated our Fine-Tuned model directly on previously published
373 data by comparing hand drawn histomorphometry outlines of the synovial tissue on slides (n=9)
374 in the Test set from the TNF-Tg cohort (Batch A) published in Bell et al 2019 [18]. There was a
375 significant positive correlation between the DL segmentation area and the hand drawn area
376 ($r^2=0.96$, **Figure 2A**) which demonstrates the accuracy of our method with hand drawn
377 histomorphometry. 2) We then validated our model in a real-world setting by collecting 171
378 slides (64 knees, 2-to-3 histologic levels per knee) from 6-to-8-month-old TNF-Tg mice treated
379 with Anti-TNF therapy for 6 weeks and slides from TNF-Tg and WT naïve and placebo-treated
380 mice used as controls [19, 47] (**Figure 2B**). Male TNF-Tg mice display a robust inflammatory
381 arthritis with synovial hyperplasia and pannus invasion of the distal femur and femoral articular
382 cartilage starting around 3 months and reaching end-stage at 8 months of age, and our model
383 measures this robust response well (**Figure 2C**, WT vs TNF-Tg, $p<0.0001$). Anti-TNF therapy is
384 known to reduce synovitis yet does not alter trabecular bone loss in mice with established
385 disease (>6 months old) [48, 49]. Our DL segmentation appropriately modeled these well-
386 established structural changes autonomously (**Figure 2 C&D**), and it uncovered that cartilage

387 degradation is also moderately reduced when Anti-TNF therapy is provided at 8 months of age
388 for 6 weeks, which is an expected but novel result. Interestingly, trabecular bone area is already
389 decreased in 6-month-old TNF-Tg mice compared to WT counterparts while cartilage area is
390 not, suggesting that trabecular bone loss occurs before cartilage loss. Additionally, multiple
391 other tissue structures can be studied simultaneously (**Supplemental Figure 7**) showing the
392 versatility of studying H&E segmentation models to assess tissue structural changes within the
393 context of mouse disease models. Taken together, these analyses suggests that our model
394 accurately detects relevant and meaningful biologic treatment effects with the potential to
395 discover novel structural changes. It is important to note that some of these slides were stained
396 with a variation of traditional H&E, H&E-Orange-G (see *Methods*) demonstrating that our
397 training strategy choices produced a model that is robust even when introducing stain
398 variations.

399

400 *Tissue-Specific and Arthritis Effector Cell Types can be Identified with ML in TNF-Tg Mice*

401 We annotated a total of 4,712 cells across three stages of murine inflammatory arthritis
402 in the TNF-Tg mice (n=6 healthy, n=8 mild disease, and n=5 severe, **Supplemental Figure 8**)
403 to build a cell type classification model that could recognize cells from various disease stages.
404 We developed novel custom feature extraction methods, and the fidelity of these methods was
405 demonstrated in 2D UMAP space, as most cell types are clearly separable (**Figure 3A**). We
406 next built a GBDT classification model using stratified 5-fold cross validation training and tested
407 our models' predictions using three methods. First, we calculated the average (\pm SD of folds) F1
408 of each cell class in the test sets (**Figure 3B**). Each cell class demonstrated a good F1,
409 between 0.61 for vessel cells and 0.92 for adipo-stromal cells with synovial associated cell
410 classifications among the best (synovial lining cells = 0.87 ± 0.03 ; synovial fibroblasts = $0.79 \pm$
411 0.05 ; and synovial lymphocytes = 0.91 ± 0.05). To validate our classification, we used two
412 strategies that utilized tissue and disease context. Tissue segmentation using the Original

413 model was performed on these training slides and the remaining >300,000 cells cell-type
414 classification was inferred. Tissues with known homogenous cell types, fat tissue and
415 cartilage/meniscus, were investigated and cell types among these tissues were plotted. Within
416 these adipose tissue and cartilage/meniscus, the most predicted cell type were adipo-stromal
417 cells and chondrocytes, respectively (**Figure 3C**). Next, to assess predictions in the context of
418 disease, we utilized the synovial tissue predictions only (as determined by the tissue
419 segmentation model **Figure 1**) and stratified by disease severity. As shown by **Figure 3D**,
420 synovial-specific increases in synovial fibroblasts, synovial lining cells and lymphocytes are
421 seen with increasing disease severity. These results suggest that our cell type model can
422 produce high quality predictions that are sensitive to disease stage.

423 Given the promising intra-test set performance and tissue- and disease-state specificity
424 of the cell type modeling, we aimed to further validate our model with a larger data-set with
425 more biologic variation. To do this, we utilize the previously described sexually dimorphic
426 synovial pathology in TNF-Tg mice [18] and collected slides from 3-to-5.5-month-old WT and
427 TNF-Tg-male and female mice. Confirming our previous observation using traditional histologic
428 scoring, we found a significant increase of lymphocytes in female TNF-Tg synovium at 3 months
429 of age with concomitant significant increase in synovial lining cells (**Figure 4A and B**).
430 Interestingly, sexual dimorphism was not observed when assessing synovial fibroblasts, which
431 is a novel finding (**Figure 4C**). Finally, we correlated our computationally derived lymphocyte
432 and synovial lining cell counts with the synovial inflammatory score and pannus score,
433 respectively (**Figure 4D and E**), and found good correlation between the parameters. This
434 relationship also held for total cell counts (**Figure 4F**).

435 To reduce the annotation time, we explored various active learning approaches
436 retrospectively in the murine cell type data set. Model performance using all the active learning
437 strategies with 45% of the total training size was comparable to using the complete dataset with
438 random sampling (0.8188 (0.8157-0.8219) vs 0.8213 (0.8184-0.8243), F1 \pm SD). Additionally,

439 with 45% of the data, the model performance using active learning was higher than using a
440 randomly sampled set of examples (0.8188 (0.8157-0.8219) vs 0.8082(0.8053-0.8111) F1 \pm SD)
441 (**Supplemental Figure 10**). Additionally, the mean 5-fold CV macro F1-score was most different
442 at the 10%-25% of annotated data range, indicating that active learning can drastically improve
443 model performance with fewer examples.

444

445 *Cell Type Modeling on Human RA Synovial Biopsies Predicts Pathotypes and Correlates with* 446 *Clinical Outcomes*

447 After validating the active learning strategy in murine tissue, we next applied this
448 approach to generate cell type annotations on human synovial tissue sections, aiming to reduce
449 the overall histopathological evaluation time for our pathologist. We collected a small subset of
450 initial annotations, predicted cell types on new cells and calculated the entropy-based
451 uncertainty, ranking the most uncertain cells for future annotation by the pathologist. After
452 multiple rounds with active learning, a total of 2,341 cells were annotated (**Supplemental**
453 **Figure 11**). Using a gradient boosted decision tree with 5-fold cross validation we achieved
454 model performance ranging from 0.74-0.88 F1-scores for all classes (**Figure 5A**). An example
455 confusion matrix from the best performing fold demonstrates that undifferentiated stromal-
456 connective cells are confused with vascular endothelial cells at the highest frequency and the
457 plasma cells and lymphocytes are also often confused with each other (**Figure 5B**). Example
458 prediction overlays demonstrate the high quality that our model produces for all our given cell
459 types (**Figure 5C**).

460 To validate model performance, cell types were quantified for the entire synovial biopsy
461 dataset with known across the three known pathotypes. Importantly, our cell type prediction a
462 consistent with the previously described cellular distribution within each pathotype [10, 11, 14,
463 50]. Specifically, synovial fibroblasts are primarily found in the pauci-immune pathotype and
464 some diffuse cases; while lymphocytes and plasma cells are found primarily in the lymphoid

465 pathotype (**Figure 6A**). Interestingly, if a simple threshold is placed at 1.1% plasma cell to
466 classify lymphoid ($\geq 1.1\%$) or diffuse ($< 1.1\%$) cases, 19 out of 24 lymphoid cases and 22 out of
467 29 diffuse cases are correctly identified. Further, lymphocyte counts strongly correlates with the
468 Krenn inflammation score (Spearman's $\rho = 0.88$, **Figure 6B**). Example images of the three
469 pathotypes and their respective predictions demonstrate the cellular distributions of these
470 pathotypes (**Figure 6C**).

471

472 **Discussion**

473 Here, we demonstrate that multi-scale modeling of synovial histopathology can
474 pathotype RA and inflammatory arthritis in clinically meaningful settings, such as treatment
475 response. Our model will reduce the analytical bottleneck associated with histopathology
476 assessment in both the clinical and preclinical settings allowing quicker times to intervention or
477 hypothesis resolution. Furthermore, it will reduce the amount of accessory immunostaining
478 required for pathotyping by using H&E stains to infer cell types, like lymphocytes and plasma
479 cells, which would otherwise need an immunohistochemical (IHC) stain to confirm specific cell
480 types. This could be very impactful as the diffuse pathotype (plasma cell poor with enrichment in
481 myeloid cells) show improved response to tocilizumab (anti-IL-6R antibody) [50] while the
482 fibroblast rich pauci-immune pathotype shows inadequate response to anti-TNF therapy [11].
483 While we did not have enough specimens to build a model to classify the pauci-immune
484 pathotype in the AMP-RA data set, we were able to classify a diffuse vs lymphoid pathotype
485 utilizing a simple threshold on plasma cell percent with a sensitivity and specificity of 0.81 and
486 0.73, respectively.

487 Computational approaches to understanding tissue and cellular information from
488 histology slides have greatly improved in recent years. Specifically, tools to segment or classify
489 of malignant tissues and cells from biopsy specimens [51], and cell type classification on

490 cytology blood smears [52] have seen the largest amount of development with many
491 applications acquiring FDA approval [53]. These tools have dramatically increase the throughput
492 of clinical histologic analysis by, for example, red flagging potential malignant cases with >0.95
493 AUC for further review [54], classifying and counting cells on cytology smears or slides for
494 detection of malignant cells and other pathologies [37, 52]. However, there is a dearth of
495 computational pathology tools outside of cancer or outside of diagnostic settings and within the
496 space of musculoskeletal pathologies [55]. Our work represents the first set of comprehensive
497 tissue and cellular analysis tools for both pre-clinical and clinical phenotyping (in this case
498 pathotyping) in inflammatory arthritis. In adjacent work, Pati and colleagues utilized hierarchical
499 graph convolutional neural networks to integrate information from both the cellular and tissue
500 levels on 2048px x 1536px sized images ($0.42 \mu\text{M}^2$ pixels) [56]. This model was largely effective
501 at detecting cancerous images with an F1 of $84.9\% \pm 0.8\%$, however did not perform well for
502 non-cancerous, pre-cancerous or normal images with F1s of $56.6 \pm 1.7\%$, $66.1 \pm 3.7\%$, and
503 $66.2 \pm 1.7\%$, respectively. In other work, HoVer-Net is a state-of-the-art nucleus segmentation
504 and cell type classification deep learning model for H&E-stained tissues [37]. However, the
505 model was originally trained to identify malignant cells from other stromal (epithelium, fibroblast,
506 muscle or endothelium) or inflammatory cells and only on small image patches. In synovial
507 biopsies from RA patients' further delineation of inflammatory cells is critical to pathotyping.
508 Thus, we utilized the nuclear segmentation portion of the model and transferred this knowledge
509 into our custom feature extraction pipeline to build a model to classify discrete immune cells
510 relevant in RA synovial pathology.

511 Some computational approaches have already been successfully applied to H&E slides
512 of synovial biopsies of RA patients to quantify cellular changes, such as nuclei density and its
513 association with clinical inflammatory measures [57], and simple counting of CD3+ T-cells or
514 CD68+ macrophages on IHC [58-60]. Further, pathologist scores of specific cells types have
515 been associated with quantitative inflammatory gene expression changes in the RA synovium

516 [61]. Our approach aimed to incorporate the important cell types from this previous work while
517 producing models that only require H&E-stained tissues. However, RA has been shown to be a
518 complex polygenic autoimmune disorder with various environmental risk factors contributing to
519 multiple etiologies [12, 62, 63]. As a consequence of this complexity, many RA patients are
520 refractory to existing approved therapies [64-67]. This highlights the need for a personalized
521 medicine approach to improve clinical trial design and treatment allocation, as done in recent
522 trials like the R4RA [6] and PEAC [68] that utilize ultrasound guided synovial biopsies and
523 pathotype evaluation to stratify patients. Our models may be able to improve the workflow of
524 these types of clinical trials and reduce the overall cost.

525 One major benefit of our model is the fact that we used H&E-stained tissues. These
526 tissues are routinely and easily collected and represent a large proportion of historical datasets
527 allowing for larger retrospective studies. While some of the computational pathology tools utilize
528 H&E-stained slides, many have utilized special stains geared towards tissue- or cell type-
529 specific classification [55]. This limits the overall throughput and utility of such pipelines by
530 adding additional steps and costs that may be prohibitive. In addition, using a common stain
531 facilitates transfer learning applications to other musculoskeletal pathologies, like osteoarthritis,
532 bone fracture or disc degeneration, with different etiologies but similar tissue involvement and
533 histopathology requirements.

534 Histopathology scoring that utilize Likert scales [69] is the gold standard analysis
535 method of histology. For RA, various types of assessment, including Krenn lining and
536 inflammation scores, rely on a consensus grading system to account for the challenge in
537 analyzing H&E-stained tissue [70]. However, many scoring mechanisms quantify high level
538 pathologic features (e.g. percent of area effected) or composite measures, without the level of
539 detail included in our pipeline. The added benefit of quantifying cellular abundance and discrete
540 tissue margins is that it can increase our ability to detect and predict the sensitivity to biological
541 or therapeutic differences over Likert scale-based histology scores. For example, in our

542 previous work we used a Likert scale to quantify synovial inflammatory infiltrate in which a score
543 of 3 corresponded to “>30 inflammatory cells thick” while in our current work we use our
544 computational approaches to count the specific number of lymphocytes that are present in the
545 synovium. This is evident when the effect size (Glassé’s d) is calculated for Female vs Male,
546 TNF-Tg, 3-month-old of the scores vs the cell counts is compared (Histologic Scoring: 2.79 vs
547 Lymphocyte Counts: 74.82) suggesting our cell classification model is orders of magnitude more
548 sensitive to biologic differences than histologic scoring. These differences in quantification
549 method represents ~25 fold increase in measured effect size at 3 months between female and
550 male TNF-Tg mice (Figure 5A) using the computational approach, suggesting a greatly enhance
551 the ability to detect very small differences in therapeutic or other interventions to modulate the
552 pathology. In addition to more granular quantification of pathology these analyses are also
553 more efficient. For example, to generate the annotations to build our segmentation model we
554 spent 200+ hours drawing annotations on the 94 slides. However, to infer the tissue segment on
555 the 174 slides in Figure 2 the model took ~30 hours of hands-off compute time with only 2-3
556 hours of labor to visualize the results, representing a ~120-fold increase in efficiency.

557 Lastly, utilizing computational tools that quantify multiple tissues and cell types improves
558 the ability to find novel phenomena. For example, while our primary focus is on the synovial
559 pathology in inflammatory arthritis, having a model that measures cartilage, meniscus, and bone
560 pathology provides a more comprehensive picture of disease. This allows easier detection of
561 off-target or unexpected therapeutic effects with a singular methodology. However, reliance
562 solely on computational modeling maybe increase false positives and expert-level quality control
563 is advised for high impact results.

564 In conclusion, we have developed a set of models that can characterize tissue and
565 cellular pathology in pre-clinical and clinical inflammatory arthritis settings. These models can be
566 leveraged to better understand disease mechanisms in pre-clinical models and be used in a
567 precision medicine pipeline to improve patients’ health.

568

569 **Acknowledgments**

570 Accelerating Medicines Partnership Program: Rheumatoid Arthritis and Systemic Lupus

571 Erythematosus (AMP RA/SLE) Network includes:

572 Jennifer Albrecht¹, William Apruzzese², Brendan F. Boyce¹, David L. Boyle³, Michael B.

573 Brenner², S. Louis Bridges Jr.¹⁰, Christopher D. Buckley⁴, Jane H. Buckner⁵, Vivian P. Bykerk^{1,3},

574 James Dolan², Thomas M. Eisenhaure⁶, Andrew Filer⁴, Gary S. Firestein³, Chamith Y.

575 Fonseka^{2,6}, Ellen M. Gravallesse⁷, Peter K. Gregersen⁸, Joel M. Guthridge⁹, Maria Gutierrez-

576 Arcelus^{2,6}, Nir Hacohen⁶, V. Michael Holers⁷, Laura B. Hughes¹⁰, Eddie A. James⁵, Judith A.

577 James⁹, A. Helena Jonsson², Josh Keegan², Stephen Kelly¹¹, James A. Lederer², Yvonne C.

578 Lee¹², David J. Lieb⁶, Arthur M. Mandelin II¹², Mandy J. McGeachy¹³, Michael A. McNamara^{1,3},

579 Joseph R. Mears^{2,6}, Nida Meednu¹, Fumitaka Mizoguchi^{2,14}, Larry Moreland¹³, Jennifer P.

580 Nguyen², Akiko Noma⁶, Chad Nusbaum⁶, Harris Perlman¹², Javier Rangel-Moreno¹, Christopher

581 T. Ritchlin¹, William H. Robinson²⁴, Mina Rohani-Pichavant²⁴, Cristina Rozo³, Karen Salomon-

582 Escoto⁷, Jennifer Seifert⁷, Anupamaa Seshadri², Kamil Slowikowski^{2,6}, Danielle Sutherby⁶,

583 Darren Tabechian¹, Jason D. Turner⁴, Paul J. Utz¹⁵, Gerald F. M. Watts², Kevin Wei²,

584 Costantino Pitzalis¹⁶, Deepak A. Rao², Michael B. Brenner², Soumya

585 Raychaudhuri²

586 ¹University of Rochester Medical Center, Rochester, NY, USA.

587 ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

588 ³University of California, San Diego, La Jolla, CA, USA.

589 ⁴University Hospitals Birmingham NHS Foundation Trust and University of Birmingham,

590 Birmingham, UK.

591 ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.

592 ⁶Broad Institute of MIT and Harvard, Cambridge, MA, USA.

593 ⁷University of Massachusetts Medical School, Worcester, MA, USA.

594 ⁸Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, NY, USA.

595 ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

596 ¹⁰University of Alabama at Birmingham, Birmingham, AL, USA.

597 ¹¹Barts Health NHS Trust, London, UK.

598 ¹²Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

599 ¹³University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

600 ¹⁴Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University,
601 Tokyo, Japan.

602 ¹⁵Stanford University School of Medicine, Palo Alto, CA, USA.

603 ¹⁶Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen
604 Mary University of London; London, UK

605

606 **Figure Legends**

607 **Figure 1. A fine-tuned 10 class model can segment relevant tissue in inflammatory**

608 **arthritis.** Mean Intersection over union (mIOU) and class frequency weighted mIOU statistics

609 from the RF and DL segmentation models are presented in A, and demonstrate that UNET++ 9

610 Class model that was then fine tuned to segment the meniscus and cartilage performs the best.

611 Representative images of H&E (B) image, with Ground Truth (GT, C), RF (D), UNET++ (E) and

612 the Fine-Tuned model's prediction overlays demonstrate the successful segmentation and

613 mistakes. Specifically, the area where the synovial pannus tissue reaches the cartilage (Bⁱⁱ - Eⁱⁱ),

614 the RF model (Dⁱⁱ) underperforms while the UNET++ (Eⁱⁱ) are almost perfect. A common

615 mistake within all models is misclassifying the trabecular bone (Bⁱⁱⁱ - Eⁱⁱⁱ) for other tissues, with

616 the RF (Dⁱⁱⁱ) model misclassifies for cartilage, muscle and tendon, and cortical bone; while

617 UNET++ (Eⁱⁱⁱ) misclassifies only as cortical bone. When investigating the overall misclassification of

618 cortical bone for trabecular bone it occurs in <5% of all tissue area. Importantly, the Fine-Tuned
619 model (F) successfully segments the Cartilage and Meniscus from each other (Fⁱⁱ and Fⁱⁱⁱ).

620

621 **Figure 2. The fine tuned UNET++ model measures treatment response in the TNF-Tg with**

622 **Anti-TNF therapy.** Inferred test set synovial area correlated excellently with previously

623 published hand drawn histomorphometry data (A). We then developed an independent cohort of

624 slides from previously published work with a biologically relevant therapeutic intervention to test

625 if our model is sensitive to detect these well described therapeutic response (B). As predicted

626 from previous work, TNF-Tg have increased synovial area and lower trabecular bone area, with

627 Anti-TNF therapy decreasing synovial area but does not alter trabecular area (C and D).

628 Interestingly, we are able to detect the loss of cartilage area at end stage disease compared to

629 younger TNF-Tg mice, and the therapeutic intervention protects from this loss (C, Right Panel).

630

631 **Figure 3. Cell type classification model successfully identifies important cell types in**

632 **inflammatory arthritis.** Utilizing Principal Component Analysis to reduce features and Uniform

633 Manifold Approximation and Projection (UMAP) to project in 3D, we see good separation of

634 Lymphocytes, Bone-Embedded Cells, Chondrocytes, and Adipo-stromal Cells (A). The gradient

635 boosted decision tree performs well with an overall F1 of 0.83 ± 0.12 ($M \pm SD$) and the class

636 specific F1 is shown in (B). We then predicted the cell class (>75% predicted probability) of all

637 other cells identified on the slides (~300,000). To provide quality control, we looked at the

638 predicted cells within the Fat tissue and Cartilage/Meniscus and our model appropriately

639 classifies the majority cells within these tissue as fat cells or chondrocytes, respectively (C). We

640 next looked at the cells within the synovium and found that our model classifies fibroblast,

641 lymphocytes and other synovial lining cells well, and their distribution meets the expectation in

642 healthy mild and severely disease knees (D).

643

644 **Figure 4. Cell type modeling recapitulates the sexual dimorphism of TNF-Tg inflammatory**
645 **arthritis** Using this model to perform cell type predictions in a sexually dimorphic model of
646 inflammatory arthritis, the computational pathology model describes previously demonstrated
647 difference in inflammatory lymphoid infiltrates (here as Lymphocytes, **A**) and synovial
648 hyperplasia (**B**, Synovial Lining cells). Interestingly, there is no difference in fibroblast cell (**C**)
649 counts between TNF-Tg male and female mice. Importantly, we found a significant correlation
650 between lymphocyte counts and the inflammatory infiltrate score (**D**); synovial lining cell counts
651 and pannus invasion score (**E**); and between the total cell count and total cell area (as originally
652 measured, **F**).

653
654 **Figure 5. Cell type modeling correctly classifies synovial stromal and immune cells in RA**
655 **synovial biopsies.** The overall average F1 from the five-folds was 0.81 ± 0.06 , with all individual
656 cell types performing well with greater than 0.75 F1 scores (A). Interrogating the confusion
657 matrix (B) from the best performing model, we see that the most common mistakes are that
658 plasma cell and lymphocytes are mistaken for each other and all the stromal cell populations
659 (Stromal/Connective cells, Vascular Endothelial cells and Synovial Lining cells) can be
660 confused. Representative images of cell class predictions with the original H&E on the top row
661 and the cell type predictions overlays on the bottom row (C). F : Fibroblast, L : Lymphoid, M/H :
662 Macrophage/Histocyte, PC : Plasma Cell, S/C : Stromal/Connective Cell, SLC : Synovial Lining
663 Cell; VEC : Vascular Endothelial Cell.

664
665 **Figure 6. Cell type modeling associates with clinical pathotypes and correlates with**
666 **clinical outcomes measures.** Cell type predictions were made on 60 RA biopsy specimens
667 (n=5 Pauci-Immune, n=27 Diffuse, n=26 Lymphoid) and plots of the Synovial Fibroblasts,
668 Lymphocytes, and Plasma Cells percent of total cells demonstrate the known clinical differences
669 among these pathotypes (**A**). We found a significant correlation between lymphocyte counts and

670 the Krenn Inflammation score (**B**). Representative H&E and prediction overlay images (**D**)

671 demonstrate the cellular diversity between the Pauci-immune, Diffuse, and Lymphoid

672 pathotypes of RA.

673

674 Supplemental Figure Legends

675 **Supplemental Figure 1. Training, Testing and Validation with batch effect study design.**

676 A) Description of Batch A from the TNF-Tg cohort and Batch B from the ZIA cohort. B)

677 Description of the two training strategies, Mixed Training and Single Batch training.

678

679 **Supplemental Figure 2. Tissue Hierarchy Annotation Strategy.** Description of the

680 hierarchical tissue classification scheme and which tissues are among each of the classes. The

681 overall frequency of each class is also reported on the right.

682

683 **Supplemental Figure 3. Examples of Image Augmentation.** The original image is provided in

684 A with Gaussian and Speckle Noise (B), Drop Out (C), Rotation (D), Hue and Saturation with

685 Drop Out(E), and Color Temperature adjustment (F).

686

687 **Supplemental Figure 4. Using highly overlapping tiles with a per pixel majority vote**

688 **produces the best performing model.** mIOU and fwIOU statistics of the three tiling

689 mechanisms are show in A (*data is also presented in in Figure 1). Representative prediction

690 overlays of the no overlap tiling strategy which shows very poor performance, and the 50%

691 overlap tiling strategy which has a prediction artifact caused by poor predictions at the edges of

692 the tiles (Arrows, B).

693

694 **Supplemental Figure 5. A mixed training strategy with high augmentation builds a high**

695 **performing segmentation model.** Staining batch effect is a major issue with histology and we

696 intentionally collected images in two different batches despite both being stained with H&E. The
697 difference in RGB distributions between the two batches (A) is shown in 3D RGB space. The
698 mean and frequency weighted IOU scores of all the mixed training models are similar and
699 outperform the single batch training (B). During single batch training, high augmentation preform
700 that best. The SLIC-RF model is provided as reference and underperforms compared to all DL
701 models. Representative images of both batches with the H&E, GT, RF, No Augmentation and
702 High Augmentation overlays are presented in C. Single batch high augmentation model
703 qualitatively produces more segmentation artifacts (arrows).

704

705 **Supplemental Figure 6. Tables of class specific mIOU's across all models.** The 7 class, 9
706 class, 10 class and 11 class model performance with each class is presented (A-C).

707

708 **Supplemental Figure 7. The UNET++ Fine Tuned 10 class model phenotypes the TNF-Tg**
709 **with Anti-TNF therapy.** The remaining 5 tissue class predictions do not show any meaningful
710 differences between the Anit-TNF and control samples.

711

712 **Supplemental Figure 8. Mouse Cell Type Classification scheme.** We selected 7 basic cell
713 types to classify and annotated on healthy (n=6), mild disease (n = 8) and severely diseased
714 (n=5) TNF-Tg slides. We annotated bone-embedded cells (A, n=312), vessel cells (B, n = 378),
715 adipo-stromal cells (C, n = 506), fibroblasts (healthy, D; diseased, E; n = 749), chondrocytes
716 (articular, F; growth plate, G; n = 625), lymphocytes (H, n = 467), and all other synovial lining
717 cells (healthy, I; diseased, J; n = 1675).

718

719 **Supplemental Figure 9. Active learning can reduce the number of training samples.** Three
720 independent active learning statistics were evaluated (Entropy, Blue; Margin, Red: Uncertainty,
721 Purple) to select cells and compared against randomly selecting cells (Green). Using the any of

722 the active learning uncertainty calculations to select new training data to add outperforms
723 random sampling overall (A, green curve is lower between 5-60%). Bone-embedded cells,
724 Synovial Fibroblasts, synovial fats cells and synovial vessel cells all demonstrate improved
725 performance with active learning while lymphocytes, synovial lining cells and growth plate
726 chondrocytes do not (B-H). Interestingly, maximal training occurred with only ~30% of the total
727 training data set, suggesting this mechanism could be used to generate new annotations on a
728 novel dataset. Note the different scale on D.

729

730 **Supplemental Figure 10. Human Cell type Classification scheme for Synovial Biopsy**

731 **Specimens.** We identified 13 cases from the Accelerating Medicine Partnership – Rheumatoid
732 Arthritis (AMP-RA) Phase 2 cohort that were distributed between the three RA synovial
733 pathotypes (Lymphoid, n = 5; Diffuse, n = 5; Pauci-Immune, n = 3). A board-certified pathologist
734 annotated 7 cell types among these 13 cases: stromal/connective tissue cells (A, n=541),
735 synovial lining cells (B, n= 314), fibroblasts (C, n = 180), vascular endothelial cells (D, n = 349),
736 Tissue Macrophages/Histocytes (E, n = 176), lymphocytes (F, Green Arrows; n = 555), and
737 plasma cells (F, Blue Arrows; n = 226). In order to obtain these annotations, we used the
738 uncertainty sampling active learning strategy as presented in Supp Figure 9 to select cells for
739 our pathologist to annotate. The table describes the general hierarchy of cell labels, for
740 example, if the pathologist could not further distinguish a stromal cell to be either a vascular
741 endothelial cell or fibroblast, then the cell would be labeled as a stromal/connective cell.

742

743

744 **References**

745

- 746 1. Firestein, G.S., *The disease formerly known as rheumatoid arthritis*. *Arthritis Res*
747 *Ther*, 2014. **16**(3): p. 114.
- 748 2. Lewis, M.J., et al., *Molecular Portraits of Early Rheumatoid Arthritis Identify*
749 *Clinical and Treatment Response Phenotypes*. *Cell Rep*, 2019. **28**(9): p. 2455-
750 2470 e5.
- 751 3. Wang, J., et al., *Synovial Inflammatory Pathways Characterize Anti-TNF-*
752 *Responsive Rheumatoid Arthritis Patients*. *Arthritis Rheumatol*, 2022. **74**(12): p.
753 1916-1927.
- 754 4. Rivellese, F., et al., *Rituximab versus tocilizumab in rheumatoid arthritis: synovial*
755 *biopsy-based biomarker analysis of the phase 4 R4RA randomized trial*. *Nat*
756 *Med*, 2022. **28**(6): p. 1256-1268.
- 757 5. Micheroli, R., et al., *Role of synovial fibroblast subsets across synovial*
758 *pathotypes in rheumatoid arthritis: a deconvolution analysis*. *RMD Open*, 2022.
759 **8**(1).
- 760 6. Humby, F., et al., *Rituximab versus tocilizumab in anti-TNF inadequate*
761 *responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a*
762 *stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled*
763 *trial*. *Lancet*, 2021. **397**(10271): p. 305-317.
- 764 7. Nerviani, A., et al., *A Pauci-Immune Synovial Pathotype Predicts Inadequate*
765 *Response to TNFalpha-Blockade in Rheumatoid Arthritis Patients*. *Front*
766 *Immunol*, 2020. **11**: p. 845.
- 767 8. Elmore, J.G., et al., *Diagnostic concordance among pathologists interpreting*
768 *breast biopsy specimens*. *Jama*, 2015. **313**(11): p. 1122-1132.

- 769 9. Elmore, J.G., et al., *Pathologists' diagnosis of invasive melanoma and*
770 *melanocytic proliferations: observer accuracy and reproducibility study.* *bmj*,
771 2017. **357**.
- 772 10. Pitzalis, C., S. Kelly, and F. Humby, *New learnings on the pathophysiology of RA*
773 *from synovial biopsies.* *Curr Opin Rheumatol*, 2013. **25**(3): p. 334-44.
- 774 11. Nerviani, A., et al., *A Pauci-Immune Synovial Pathotype Predicts Inadequate*
775 *Response to TNF α -Blockade in Rheumatoid Arthritis Patients.* *Front Immunol*,
776 2020. **11**: p. 845.
- 777 12. Rivellese, F., et al., *Rituximab versus tocilizumab in rheumatoid arthritis: synovial*
778 *biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.* *Nature*
779 *medicine*, 2022. **28**(6): p. 1256-1268.
- 780 13. Humby, F., et al., *Synovial cellular and molecular signatures stratify clinical*
781 *response to csDMARD therapy and predict radiographic progression in early*
782 *rheumatoid arthritis patients.* *Ann Rheum Dis*, 2019. **78**(6): p. 761-772.
- 783 14. Manzo, A., et al., *Histopathology of the synovial tissue: perspectives for*
784 *biomarker development in chronic inflammatory arthritides.* *Reumatismo*, 2018.
785 **70**(3): p. 121-132.
- 786 15. Chang, M.H. and P.A. Nigrovic, *Antibody-dependent and -independent*
787 *mechanisms of inflammatory arthritis.* *JCI Insight*, 2019. **4**(5).
- 788 16. Raciti, P., et al., *Clinical Validation of Artificial Intelligence–Augmented Pathology*
789 *Diagnosis Demonstrates Significant Gains in Diagnostic Accuracy in Prostate*
790 *Cancer Detection.* *Archives of Pathology & Laboratory Medicine*, 2022.

- 791 17. Konnaris, M.A., et al., *Computational pathology for musculoskeletal conditions*
792 *using machine learning: advances, trends, and challenges*. Arthritis Research &
793 Therapy, 2022. **24**(1): p. 1-15.
- 794 18. Bell, R.D., et al., *Selective sexual dimorphisms in musculoskeletal and*
795 *cardiopulmonary pathologic manifestations and mortality incidence in the tumor*
796 *necrosis factor–transgenic mouse model of rheumatoid arthritis*. Arthritis &
797 Rheumatology, 2019. **71**(9): p. 1512-1523.
- 798 19. Bell, R.D., et al., *iNOS dependent and independent phases of lymph node*
799 *expansion in mice with TNF-induced inflammatory-erosive arthritis*. Arthritis Res
800 Ther, 2019. **21**(1): p. 240.
- 801 20. Frasnelli, M.E., et al., *TLR2 modulates inflammation in zymosan-induced arthritis*
802 *in mice*. Arthritis Res Ther, 2005. **7**(2): p. 1-10.
- 803 21. Kenney, H.M., et al., *Persistent popliteal lymphatic muscle cell coverage defects*
804 *despite amelioration of arthritis and recovery of popliteal lymphatic vessel*
805 *function in TNF-Tg mice following anti-TNF therapy*. Scientific Reports, 2022.
806 **12**(1): p. 12751.
- 807 22. Zhang, F., et al., *Cellular deconstruction of inflamed synovium defines diverse*
808 *inflammatory phenotypes in rheumatoid arthritis*. BioRxiv, 2022: p. 2022.02.
809 25.481990.
- 810 23. Krenn, V., et al., *Grading of chronic synovitis--a histopathological grading system*
811 *for molecular and diagnostic pathology*. Pathol Res Pract, 2002. **198**(5): p. 317-
812 25.

- 813 24. Bankhead, P., et al., *QuPath: Open source software for digital pathology image*
814 *analysis*. Scientific reports, 2017. **7**(1): p. 1-7.
- 815 25. Campanella, G., et al., *Clinical-grade computational pathology using weakly*
816 *supervised deep learning on whole slide images*. Nature medicine, 2019. **25**(8):
817 p. 1301-1309.
- 818 26. Howard, F.M., et al., *The impact of site-specific digital histology signatures on*
819 *deep learning model accuracy and bias*. Nature communications, 2021. **12**(1): p.
820 1-13.
- 821 27. *imgaug: a library for image augmentation in machine learning experiments*. 2023
822 5/21/23].
- 823 28. Bradski, G. *The OpenCV Library*. 2000 5/21/23]; Available from:
824 <https://opencv.org/>.
- 825 29. Zhou, Z., et al. *Unet++: A nested u-net architecture for medical image*
826 *segmentation*. in *Deep Learning in Medical Image Analysis and Multimodal*
827 *Learning for Clinical Decision Support: 4th International Workshop, DLMIA 2018,*
828 *and 8th International Workshop, ML-CDS 2018, Held in Conjunction with MICCAI*
829 *2018, Granada, Spain, September 20, 2018, Proceedings 4*. 2018. Springer.
- 830 30. Paszke, A., et al., *Pytorch: An imperative style, high-performance deep learning*
831 *library*. Advances in neural information processing systems, 2019. **32**.
- 832 31. Iakubovskii, P. *Segmentation Models Pytorch*. 2019; Available from:
833 https://github.com/qubvel/segmentation_models.pytorch.
- 834 32. Tan, M. and Q. Le. *Efficientnet: Rethinking model scaling for convolutional neural*
835 *networks*. in *International conference on machine learning*. 2019. PMLR.



- 836 33. Taghanaki, S.A., et al., *Combo loss: Handling input and output imbalance in*
837 *multi-organ segmentation*. Computerized Medical Imaging and Graphics, 2019.
838 **75**: p. 24-33.
- 839 34. Chan, L., et al. *Histosegnet: Semantic segmentation of histological tissue type in*
840 *whole slide images*. in *Proceedings of the IEEE/CVF International Conference on*
841 *Computer Vision*. 2019.
- 842 35. Thoma, M., *A survey of semantic segmentation*. arXiv preprint arXiv:1602.06541,
843 2016.
- 844 36. Stokbro, K., et al., *Does Mandible-First Sequencing Increase Maxillary Surgical*
845 *Accuracy in Bimaxillary Procedures?* J Oral Maxillofac Surg, 2019. **77**(9): p.
846 1882-1893.
- 847 37. Graham, S., et al., *Hover-Net: Simultaneous segmentation and classification of*
848 *nuclei in multi-tissue histology images*. Med Image Anal, 2019. **58**: p. 101563.
- 849 38. Gamper, J., et al., *Pannuke dataset extension, insights and baselines*. arXiv
850 preprint arXiv:2003.10778, 2020.
- 851 39. Schindelin, J., et al., *Fiji: an open-source platform for biological-image analysis*.
852 Nature methods, 2012. **9**(7): p. 676-682.
- 853 40. Ruifrok, A.C. and D.A. Johnston, *Quantification of histochemical staining by color*
854 *deconvolution*. Analytical and quantitative cytology and histology, 2001. **23**(4): p.
855 291-299.
- 856 41. Wang, X., et al., *Spatial interplay patterns of cancer nuclei and tumor-infiltrating*
857 *lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors*.
858 Science Advances, 2022. **8**(22): p. eabn3966.




- 859 42. Joshi, A.J., F. Porikli, and N. Papanikolopoulos. *Multi-class active learning for*
860 *image classification*. in *2009 IEEE conference on computer vision and pattern*
861 *recognition*. 2009. IEEE.
- 862 43. Lewis, D.D. and J. Catlett, *Heterogeneous uncertainty sampling for supervised*
863 *learning*, in *Machine learning proceedings 1994*. 1994, Elsevier. p. 148-156.
- 864 44. Tivadar Danka, P.H., *modAL: A modular active learning framework for*
865 *Pythonmodular active learning framework for {P}ython*. arXiv.
- 866 45. L. McInnes, J.H., N Saul, L GroBberger, *UMAP: Uniform Manifold Approximation*
867 *and Projection*. The Journal of Open Source Software, 2018. **3**(29): p. 861.
- 868 46. Tellez, D., et al., *Quantifying the effects of data augmentation and stain color*
869 *normalization in convolutional neural networks for computational pathology*.
870 *Medical image analysis*, 2019. **58**: p. 101544.
- 871 47. Kenney, H.M., et al., *Persistent popliteal lymphatic muscle cell coverage defects*
872 *despite amelioration of arthritis and recovery of popliteal lymphatic vessel*
873 *function in TNF-Tg mice following anti-TNF therapy*. Sci Rep, 2022. **12**(1): p.
874 12751.
- 875 48. Yi, X., et al., *TNF-Polarized Macrophages Produce Insulin-like 6 Peptide to*
876 *Stimulate Bone Formation in Rheumatoid Arthritis in Mice*. J Bone Miner Res,
877 2021. **36**(12): p. 2426-2439.
- 878 49. Shealy, D.J., et al., *Anti-TNF-alpha antibody allows healing of joint damage in*
879 *polyarthritic transgenic mice*. Arthritis Res, 2002. **4**(5): p. R7.

- 880 50. Rivellese, F., et al., *Rituximab versus tocilizumab in rheumatoid arthritis: synovial*
881 *biopsy-based biomarker analysis of the phase 4 R4RA randomized trial*. Nat
882 Med, 2022. **28**(6): p. 1256-1268.
- 883 51. Cifci, D., et al., *AI in Computational Pathology of Cancer: Improving Diagnostic*
884 *Workflows and Clinical Outcomes?* Annual Review of Cancer Biology, 2023. **7**(1):
885 p. undefined-undefined.
- 886 52. Jiang, H., et al., *Deep learning for computational cytology: A survey*. Med Image
887 Anal, 2023. **84**: p. 102691.
- 888 53. Muehlematter, U.J., P. Daniore, and K.N. Vokinger, *Approval of artificial*
889 *intelligence and machine learning-based medical devices in the USA and Europe*
890 *(2015-20): a comparative analysis*. Lancet Digit Health, 2021. **3**(3): p. e195-e203.
- 891 54. Campanella, G., et al., *Clinical-grade computational pathology using weakly*
892 *supervised deep learning on whole slide images*. Nat Med, 2019. **25**(8): p. 1301-
893 1309.
- 894 55. Konnaris, M.A., et al., *Computational pathology for musculoskeletal conditions*
895 *using machine learning: advances, trends, and challenges*. Arthritis Res Ther,
896 2022. **24**(1): p. 68.
- 897 56. Pati, P., et al., *Hierarchical graph representations in digital pathology*. Med Image
898 Anal, 2022. **75**: p. 102264.
- 899 57. Guan, S., et al., *Rheumatoid Arthritis Synovial Inflammation Quantification Using*
900 *Computer Vision*. ACR Open Rheumatology, 2022. **4**(4): p. 322-331.
- 901 58. Kraan, M.C., et al., *Quantification of the cell infiltrate in synovial tissue by digital*
902 *image analysis*. Rheumatology (Oxford), 2000. **39**(1): p. 43-9.

- 903 59. Haringman, J.J., et al., *Synovial tissue macrophages: a sensitive biomarker for*
904 *response to treatment in patients with rheumatoid arthritis*. Ann Rheum Dis,
905 2005. **64**(6): p. 834-8.
- 906 60. Rooney, T., et al., *Microscopic measurement of inflammation in synovial tissue:*
907 *inter-observer agreement for manual quantitative, semiquantitative and*
908 *computerised digital image analysis*. Ann Rheum Dis, 2007. **66**(12): p. 1656-60.
- 909 61. Orange, D.E., et al., *Identification of three rheumatoid arthritis disease subtypes*
910 *by machine learning integration of synovial histologic features and RNA*
911 *sequencing data*. Arthritis & Rheumatology, 2018. **70**(5): p. 690-701.
- 912 62. Firestein, G.S., *The disease formerly known as rheumatoid arthritis*. Arthritis
913 research & therapy, 2014. **16**: p. 1-3.
- 914 63. Mizoguchi, F., et al., *Functionally distinct disease-associated fibroblast subsets in*
915 *rheumatoid arthritis*. Nature communications, 2018. **9**(1): p. 789.
- 916 64. Buch, M.H., *Defining refractory rheumatoid arthritis*. Annals of the rheumatic
917 diseases, 2018. **77**(7): p. 966-969.
- 918 65. Smolen, J.S., et al., *Rheumatoid arthritis*. Nat Rev Dis Primers, 2018. **4**: p.
919 18001.
- 920 66. Fraenkel, L., et al., *2021 American College of Rheumatology guideline for the*
921 *treatment of rheumatoid arthritis*. Arthritis & Rheumatology, 2021. **73**(7): p. 1108-
922 1123.
- 923 67. Donlin, L.T., *Inching closer to precision treatment for rheumatoid arthritis*. Nature
924 Medicine, 2022. **28**(6): p. 1129-1131.





- 925 68. Lliso-Ribera, G., et al., *Synovial tissue signatures enhance clinical classification*
926 *and prognostic/treatment response algorithms in early inflammatory arthritis and*
927 *predict requirement for subsequent biological therapy: results from the*
928 *pathobiology of early arthritis cohort (PEAC)*. Ann Rheum Dis, 2019. **78**(12): p.
929 1642-1652.
- 930 69. Likert, R., *A technique for the measurement of attitudes*. Archives of Psychology,
931 1932. **22 140**: p. 55-55.
- 932 70. Zhang, F., et al., *Defining inflammatory cell states in rheumatoid arthritis joint*
933 *synovial tissues by integrating single-cell transcriptomics and mass cytometry*.
934 Nature immunology, 2019. **20**(7): p. 928-942.
935


A

A**B****C****D**

WT, 6mo

TNF-Tg, 6mo


WT, Placebo,
9.5 moTNF, Placebo,
9.5 moTNF, Anti-TNF,
9.5 mo

A**B**



Class	F1 (Mean \pm SD of folds)
Bone-Embedded Cells	0.87 \pm 0.03
Chondrocytes	0.89 \pm 0.06
Lymphocytes	0.91 \pm 0.05
Adipo-Stromal Cell	0.92 \pm 0.04
Fibroblasts	0.79 \pm 0.05
Synovial Lining Cells	0.87 \pm 0.03
Vessel Cells	0.61 \pm 0.16

C


Predicted Cells in Fat Tissue









Predicted Cells in Cartilage and Meniscus Tissue

**D**

■ Unlabeled Cells ■ Fibroblast
■ Lymphocytes ■ Synovial Lining Cells






A

Class	F1 (Mean \pm SD of folds)
Fibroblasts	0.77 \pm 0.04
Lymphocytes	0.87 \pm 0.01
Macrophages/ Histiocytes	0.82 \pm 0.05
Plasma Cell	0.74 \pm 0.06
Stromal/ Connective	0.75 \pm 0.02
Synovial Lining Cell	0.88 \pm 0.03
Vascular Endothelial Cell	0.79 \pm 0.02

B

True Labels



■ Lymphocytes
 ■ Unlabeled Cell
 ■ Fibroblast

■ Vascular Endothelial Cell
 ■ Plasma Cell
 ■ Macrophage/
Histiocyte
 ■ Synovial Lining
Cell
 ■ Stromal/
Connective

C